C

Corvus Pharmaceuticals
D

CRVS

20.690
USD
-0.22
(-1.05%)
مغلق
حجم التداول
81,899
الربح لكل سهم
-1
العائد الربحي
-
P/E
-38
حجم السوق
1,733,152,679
أصول ذات صلة المقالات

العنوان: Corvus Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).